[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=d7ae8521c346d1f3a8bb1b68a6302a95106760820b86e4504842c4009922b16d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752511140,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 135952251,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=d7ae8521c346d1f3a8bb1b68a6302a95106760820b86e4504842c4009922b16d"
    }
  },
  {
    "ts": null,
    "headline": "Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research",
    "summary": "Originally published by The Robert A. Winn Excellence In Clinical Trials Award Program NORTHAMPTON, MA / ACCESS Newswire / July 14, 2025 / The Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP), a national program out of VCU Massey Comprehensive ...",
    "url": "https://finnhub.io/api/news?id=516127d3516bf23e9cc14d3f55f1636d3628955c2d1d84f0c90afb3c8ba02995",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752501600,
      "headline": "Winn CIPP Welcomes Cohort 4 Medical Students Focused on Connecting Communities to Clinical Research",
      "id": 135927829,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Originally published by The Robert A. Winn Excellence In Clinical Trials Award Program NORTHAMPTON, MA / ACCESS Newswire / July 14, 2025 / The Robert A. Winn Clinical Investigator Pathway Program (Winn CIPP), a national program out of VCU Massey Comprehensive ...",
      "url": "https://finnhub.io/api/news?id=516127d3516bf23e9cc14d3f55f1636d3628955c2d1d84f0c90afb3c8ba02995"
    }
  },
  {
    "ts": null,
    "headline": "Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board",
    "summary": "MADISON, Wis., July 14, 2025--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies.",
    "url": "https://finnhub.io/api/news?id=cb4428f46999bf5835f63b8a4f94ac3ad8674b6ce14a9d4f8fa8b87ec2ec48d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752501120,
      "headline": "Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board",
      "id": 135926359,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "MADISON, Wis., July 14, 2025--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies.",
      "url": "https://finnhub.io/api/news?id=cb4428f46999bf5835f63b8a4f94ac3ad8674b6ce14a9d4f8fa8b87ec2ec48d4"
    }
  },
  {
    "ts": null,
    "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
    "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
    "url": "https://finnhub.io/api/news?id=52d5ce7b31042c98af7cdf23beb2f01cfaceeb729885e90c16732bed511985ff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752498602,
      "headline": "3 Top Dividend Stocks to Maximize Your Retirement Income",
      "id": 135927832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The traditional retirement planning approaches no longer cover all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.",
      "url": "https://finnhub.io/api/news?id=52d5ce7b31042c98af7cdf23beb2f01cfaceeb729885e90c16732bed511985ff"
    }
  },
  {
    "ts": null,
    "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
    "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
    "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752490011,
      "headline": "AnaptysBio: Potential Promise, But Some Cause For Skepticism",
      "id": 135926879,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2192786673/image_2192786673.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "AnaptysBioâs lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find out why ANAB stock is a hold.",
      "url": "https://finnhub.io/api/news?id=a8f2a499ca9319c5d73cf6d5524bcd8a35a420e9b32cb33fb26f779c2f4e0f05"
    }
  },
  {
    "ts": null,
    "headline": "Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?",
    "summary": "Style Box ETF report for ONEV",
    "url": "https://finnhub.io/api/news?id=1ff995452a0f8ab2db0df89e531869b00d82ee7787114c676980455288c02fb4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752488406,
      "headline": "Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?",
      "id": 135923529,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Style Box ETF report for ONEV",
      "url": "https://finnhub.io/api/news?id=1ff995452a0f8ab2db0df89e531869b00d82ee7787114c676980455288c02fb4"
    }
  },
  {
    "ts": null,
    "headline": "Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?",
    "summary": "Style Box ETF report for FVD",
    "url": "https://finnhub.io/api/news?id=2166e58168f940e84ce7f415ac539fa8a8871cb6b81dbe5a072e0a846027fe6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752488405,
      "headline": "Should First Trust Value Line Dividend ETF (FVD) Be on Your Investing Radar?",
      "id": 135923750,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Style Box ETF report for FVD",
      "url": "https://finnhub.io/api/news?id=2166e58168f940e84ce7f415ac539fa8a8871cb6b81dbe5a072e0a846027fe6f"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech: More Uncertainty Emerges",
    "summary": "BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out why I rate BNTX stock a hold for now.",
    "url": "https://finnhub.io/api/news?id=c57784163ba406f133afd078c10440fa7c40af310f371d08ab2f221fa2869300",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752485672,
      "headline": "BioNTech: More Uncertainty Emerges",
      "id": 135925313,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1303457428/image_1303457428.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out why I rate BNTX stock a hold for now.",
      "url": "https://finnhub.io/api/news?id=c57784163ba406f133afd078c10440fa7c40af310f371d08ab2f221fa2869300"
    }
  },
  {
    "ts": null,
    "headline": "What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report",
    "summary": "Bristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in earnings.",
    "url": "https://finnhub.io/api/news?id=b4decf5f0a2c8144c6813215800b510133a07c4dcf497923cf02842780e6f112",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752477490,
      "headline": "What to Expect From Bristol-Myers Squibb's Q2 2025 Earnings Report",
      "id": 135921135,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb is set to announce its second-quarter results by the end of July, and analysts expect a notable drop in earnings.",
      "url": "https://finnhub.io/api/news?id=b4decf5f0a2c8144c6813215800b510133a07c4dcf497923cf02842780e6f112"
    }
  }
]